These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 6775094)

  • 41. A new combination of conjugated equine oestrogens and medroxyprogesterone for treatment of climacteric complaints.
    Cullberg G; Knutsson F; Mattsson LA
    Maturitas; 1984 Jul; 6(1):55-63. PubMed ID: 6088950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Clinical effects of metharmon F for postmenopausal women with climacteric symptoms: its relationship with serum level of hormones].
    Yoshimoto S; Fujita T
    Horumon To Rinsho; 1983 Aug; 31(8):815-22. PubMed ID: 6414748
    [No Abstract]   [Full Text] [Related]  

  • 43. The menopause.
    Brenner PF
    West J Med; 1982 Mar; 136(3):211-9. PubMed ID: 7090370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma levels of estrogen, luteinizing hormone, and follicle stimulating hormone following castration and estradiol implant.
    Hunter DJ; Julier D; Franklin M; Green E
    Obstet Gynecol; 1977 Feb; 49(2):180-5. PubMed ID: 834401
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma FSH, LH and prolactin levels in postmenopausal women undergoing cyclofenil treatment.
    Nencioni T; Miragoli A; Bertaglia MG; Parini J
    Acta Obstet Gynecol Scand; 1982; 61(6):487-90. PubMed ID: 6299050
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V; Sangthawan M
    J Med Assoc Thai; 2007 Sep; 90(9):1720-6. PubMed ID: 17957910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Applied relaxation and oral estradiol treatment of vasomotor symptoms in postmenopausal women.
    Nedstrand E; Wijma K; Wyon Y; Hammar M
    Maturitas; 2005 Jun; 51(2):154-62. PubMed ID: 15917156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progestins increase endogenous opioid peptide activity in postmenopausal women.
    Casper RF; Alapin-Rubillovitz S
    J Clin Endocrinol Metab; 1985 Jan; 60(1):34-6. PubMed ID: 3155455
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone.
    Hargrove JT; Maxson WS; Wentz AC; Burnett LS
    Obstet Gynecol; 1989 Apr; 73(4):606-12. PubMed ID: 2538787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause.
    Sherwin BB; Gelfand MM
    Am J Obstet Gynecol; 1984 Mar; 148(5):552-7. PubMed ID: 6367474
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy.
    Tuomikoski P; Haapalahti P; Sarna S; Ylikorkala O; Mikkola TS
    Ann Med; 2010 Jul; 42(5):334-43. PubMed ID: 20429800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms.
    Bouchard P; Panay N; de Villiers TJ; Vincendon P; Bao W; Cheng RJ; Constantine G
    Climacteric; 2012 Feb; 15(1):12-20. PubMed ID: 22066790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maintenance of sexual function in a castrated man treated with ovarian steroids.
    Davidson JM; Camargo C; Smith ER; Kwan M
    Arch Sex Behav; 1983 Jun; 12(3):263-74. PubMed ID: 6309119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of progestational agents for postmenopausal hot flushes.
    Roopnarinesingh S
    Int J Gynaecol Obstet; 1982 Apr; 20(2):133-5. PubMed ID: 6125433
    [No Abstract]   [Full Text] [Related]  

  • 55. The treatment of postmenopausal syndrome by monthly oral doses of quinestrol.
    Jaschevatzky OE; Anderman S; Shalit A; Kampf D; Grünstein S
    Acta Obstet Gynecol Scand; 1979; 58(2):175-8. PubMed ID: 452871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Circadian pattern of prolactin secretion in postmenopausal women receiving estrogen with or without progestin.
    Chang RJ; Davidson BJ; Carlson HE; Judd HL
    Am J Obstet Gynecol; 1982 Oct; 144(4):402-7. PubMed ID: 7124858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Veralipride for hot flushes induced by a gonadotropin-releasing hormone agonist: a controlled study.
    Vercellini P; Sacerdote P; Trespidi L; Manfredi B; Panerai AE; Crosignani PG
    Fertil Steril; 1994 Nov; 62(5):938-42. PubMed ID: 7926138
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Flushing. Long-term side effect of orchiectomy in treatment of prostatic carcinoma.
    Charig CR; Rundle JS
    Urology; 1989 Mar; 33(3):175-8. PubMed ID: 2465644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of long term hormone replacement on plasma prolactin concentrations in women after oophorectomy.
    Barlow DH; Beastall GH; Abdalla HI; Elias-Jones J; Lindsay R; Hart DM
    Br Med J (Clin Res Ed); 1985 Feb; 290(6468):589-91. PubMed ID: 3918684
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The alternative to hormonal treatment of menopausal vasomotor flushes: veralipride].
    Wesel S; Bosuma WB
    Sem Hop; 1983 Mar; 59(9):596-9. PubMed ID: 6304907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.